X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare, Analyse ASTRAZENECA PHARMA with ADCOCK INGRAM HOLDINGS LTD. - S. Africa - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ASTRAZENECA PHARMA vs ADCOCK INGRAM (S. Africa) - Comparison Results

ASTRAZENECA PHARMA    Change

AstraZeneca Pharma India Limited (APIL) is a 90% subsidiary of the UK based AstraZeneca Pharmaceuticals, which is one of the world's leading pharma companies. APIL has interests in the six crucial areas of cardiovascular, respiratory, maternal health... More

ADCOCK INGRAM (S. Africa)
   Change

Adcock Ingram is a leading South African pharmaceutical manufacturer, marketer and distributor. The company occupies 10% share of the private pharmaceutical market in South Africa with a strong presence in over-the-counter (OTC) brands. Adcock is als... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 ASTRAZENECA PHARMA   ADCOCK INGRAM
EQUITY SHARE DATA
    ASTRAZENECA PHARMA
Mar-14
ADCOCK INGRAM
Jun-14
ASTRAZENECA PHARMA/
ADCOCK INGRAM
5-Yr Chart
Click to enlarge
High Rs1,285377-   
Low Rs634272-   
Sales per share (Unadj.) Rs189.6112.1-  
Earnings per share (Unadj.) Rs-0.2-28.3-  
Cash flow per share (Unadj.) Rs3.8-23.4-  
Dividends per share (Unadj.) Rs00-  
Dividend yield (eoy) %00-  
Book value per share (Unadj.) Rs68.688.0-  
Shares outstanding (eoy) m25.00168.78-   
Bonus/Rights/Conversions ---  
Price / Sales ratio x5.12.9 174.9%   
Avg P/E ratio x-4,712.7-11.5 41,041.7%  
P/CF ratio (eoy) x249.6-13.9 -1,801.3%  
Price / Book Value ratio x14.03.7 379.2%  
Dividend payout %00-   
Avg Mkt Cap Rs m23,98854,766 43.8%   
No. of employees `0001.64.3 36.3%   
Total wages/salary Rs m1,6053,437 46.7%   
Avg. sales/employee Rs Th3,040.24,409.0 69.0%   
Avg. wages/employee Rs Th1,029.2800.7 128.6%   
Avg. net profit/employee Rs Th-3.3-1,111.0 0.3%   
INCOME DATA
Net Sales Rs m4,74018,928 25.0%  
Other income Rs m92133 69.5%   
Total revenues Rs m4,83219,061 25.3%   
Gross profit Rs m-130-3,280 4.0%  
Depreciation Rs m101817 12.4%   
Interest Rs m0513 0.0%   
Profit before tax Rs m-139-4,477 3.1%   
Minority Interest Rs m0-12 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m1390-   
Tax Rs m5280 1.8%   
Profit after tax Rs m-5-4,769 0.1%  
Gross profit margin %-2.7-17.3 15.8%  
Effective tax rate %-3.7-6.2 58.6%   
Net profit margin %-0.1-25.2 0.4%  
BALANCE SHEET DATA
Current assets Rs m2,72613,863 19.7%   
Current liabilities Rs m2,4357,800 31.2%   
Net working cap to sales %6.132.0 19.2%  
Current ratio x1.11.8 63.0%  
Inventory Days Days74111 66.5%  
Debtors Days Days41124 32.9%  
Net fixed assets Rs m1,0358,081 12.8%   
Share capital Rs m5088 56.9%   
"Free" reserves Rs m9420-   
Net worth Rs m1,71614,856 11.6%   
Long term debt Rs m05,221 0.0%   
Total assets Rs m4,15628,065 14.8%  
Interest coverage xNM-7.7-  
Debt to equity ratio x00.4 0.0%  
Sales to assets ratio x1.10.7 169.1%   
Return on assets %-0.1-15.2 0.8%  
Return on equity %-0.3-32.1 0.9%  
Return on capital %0-19.8 0.0%  
Exports to sales %5.70-   
Imports to sales %6.50-   
Net fx Rs m-960-   
CASH FLOW
From Operations Rs m-81,616 -0.5%  
From Investments Rs m-146-496 29.4%  
From Financial Activity Rs m8624,738 18.2%  
Net Cashflow Rs m7095,858 12.1%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for ADCOCK INGRAM (S. Africa) is South Africa Rand. All data has been converted at 5.2 Rs / ZAR

Compare ASTRAZENECA PHARMA With: ACTAVIS (US)  MYLAN (US)  TEVA PHARMA (Israel)  

Compare ASTRAZENECA PHARMA With: CIPLA  WYETH LTD  STERLING BIOTECH  ALEMBIC PHARMA  MERCK LTD  



Today's Market

Sensex Ends Above 35,000 Mark; Bank & IT Stocks Outperform(Closing)

After opening the day flat, share markets in India witnessed positive trading activity throughout the day and ended the day on a strong note.

Related Views On News

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

Lupin: US Markets Drags down Revenues and Net Profits (Quarterly Results Update - Detailed)

Nov 2, 2017

Domestic markets registers robust growth in the quarter

More Views on News

Most Popular

Retail Investors or Chickens Waiting to Get Slaughtered in the Stock Market?(Vivek Kaul's Diary)

Jan 9, 2018

The price to earnings ratio of the Nifty 50 is very close to all-time high levels.

Is it Wise to Ignore Bitcoins?(The 5 Minute Wrapup)

Jan 4, 2018

While investing in bitcoins, it would make sense to treat it as another asset class and decide accordingly.

Best ELSS Funds In 2018: Don't Blindly Chase Top Performers(Outside View)

Jan 10, 2018

As the tax-saving season begins, investors hunt for the best ELSS funds for 2018. PersonalFN provides a list of the top ELSS mutual funds of the past year.

Resolutions for 2018 - by others(The Honest Truth)

Jan 8, 2018

Ten quirky new year resolutions. Guess by whom?

Bitcoin Beginners Should Do These Three Things...(Smart Contrarian)

Jan 10, 2018

Three simple points to keep in mind before you consider buying bitcoin.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ASTRAZENECA PHARMA SHARE PRICE


Jan 17, 2018 (Close)

TRACK ASTRAZENECA PHARMA

  • Track your investment in ASTRAZENECA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ASTRAZENECA PHARMA

ASTRAZENECA PHARMA 8-QTR ANALYSIS

COMPARE ASTRAZENECA PHARMA WITH

MARKET STATS